UPDATE: US FTC clears Pfizer buy of Hospira, but with conditions

The US Federal Trade Commission has terminated the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, with respect to US pharma giant Pfizer’s (NYSE: PFE) pending $17 billion acquisition of Hospira (NYSE: HSP).

The FTC’s clearance is contingent on Pfizer’s commitment to divest four US sterile injectable assets, including acetylcysteine for the treatment of paracetamol overdose, the antibiotic clindamycin, antifungal voriconazole and chemotherapy agent melphalan.

Alvogen is proposed buyer